Can ‘Abuse-Deterrent’ Oxycodone Help Calm Fears About Opioids?
By Crystal Lindell
When I first saw the news about an “abuse-deterrent” formulation of oxycodone being approved by the FDA, I was skeptical. What exactly was sacrificed to be worthy of such a claim?
However, after reading more about it, I am here to report that RoxyBond — which is made by Protega Pharmaceuticals — could be the opioid medication that pain patients have been waiting for. In a perfect world, RoxyBond won’t just treat pain, it may also help calm fears about opioid addiction and overdoses.
RoxyBond is not new. It’s already available in 5mg, 15mg and 30mg tablets. What the FDA did was approve a new 10mg tablet, making it the first immediate-release opioid of that dosage with abuse-deterrent properties. Most abuse deterrent opioids are extended-release medications.
“Abuse-deterrent” essentially means the tablets are so hard they cannot easily be crushed or dissolved in order to snort or inject them for a quick high. In the case of RoxyBond, that’s due to special coating and chemical make-up called SentryBond.
Protega describes SentryBond as “technology [that] combines inactive excipients with active pharmaceutical ingredients to make the tablet more difficult to manipulate for misuse and abuse.”
The noteworthy part for patients is that SentryBond makes the medication harder to abuse without the use of an opioid antagonist like naloxone. In other words, RoxyBond does not contain what a lay person may call an opioid antidote. That’s good news because naloxone can make opioids less effective and can distort a patient’s tolerance levels.
Protega says RoxyBond’s formulation is “expected to reduce abuse by intranasal and intravenous routes,” but there is also an interesting caveat in their press release.
An asterisk points readers to this disclaimer: "Abuse is still possible by intranasal, intravenous, and oral routes." That’s what previous studies have found about pills that are hardened as an abuse deterrent, so I’m not sure if RoxyBond will actually prevent abuse.
And, to be honest, that’s not what I’m concerned about. I’m much more interested in how the medication’s “abuse-deterrent” descriptor will impact prescribers and the DEA. Perhaps it’s naive of me, but my hope is that doctors and nurses will see those magic adjectives and feel more comfortable about prescribing opioids.
And — while this is perhaps even more naive — the best outcome would be for the DEA to see RoxyBond as a “safe” pain medication.
Years ago, the FDA put out a call for companies to develop abuse-deterrent opioid medications just like Roxbody, writing:
“The FDA looks forward to a future in which most or all opioid medications are available in formulations that are less susceptible to abuse than the formulations that are on the market today. To achieve this goal, FDA is taking steps to incentivize and support the development of opioid medications with progressively better abuse-deterrent properties.”
The fact that the FDA has now approved multiple doses of RoxyBond, and that the medication was basically made at the request of the government, gives me some hope that the DEA will see the tablets as less dangerous than other opioids and won’t target doctors who prescribe it.
If doctors and the DEA need adjectives like “abuse-deterrent” in order to feel safe treating pain, then that’s a small price for patients to pay. Especially since it sounds like RoxyBond is just as effective as other opioids when it comes to treating pain.
Protega says SentryBond “could potentially be utilized in other medications” like hydromorphone and hydrocodone, so we may be seeing its use expanded.
An interesting side note about SentryBond technology is that it was originally developed in a partnership with Daiichi Sankyo. But the Japanese drug maker walked away from its $200 million investment because it feared becoming entangled in U.S. opioid litigation. That’s how much litigation has disrupted American pain care.
Of course, there is still one glaring problem here. RoxyBond has already been approved in different doses, but it’s not widely known and there doesn’t seem to be much interest from doctors. I have helped multiple elderly relatives navigate their healthcare over the last few years, and I have never once heard a doctor mention RoxyBond as an option for pain management.
Maybe the news of a new dose being approved will help make prescribers more aware of RoxyBond. Maybe it just needs more time on the market.
Unfortunately, for many patients in pain, time is not something we have a lot of. We need effective treatments today, because many of us don’t know how we’ll get through tomorrow.